>https://2020news.de/wp-content/uploads/2020/12/Wodarg_Yeadon_EMA_Petition_Pfizer_Trial_FINAL_01DEC2020_EN_unsigned_with_Exhibits.pdf
XI. Several vaccine candidates are expected to induce the formation of humoral antibodies
against spike proteins of SARS-CoV-2. Syncytin-1 (see Gallaher, B., “Response to nCoV2019
Against Backdrop of Endogenous Retroviruses” - http://virological.org/t/response-to-ncov2019-
against-backdrop-of-endogenous-retroviruses/396), which is derived from human endogenous
retroviruses (HERV) and is responsible for the development of a placenta in mammals and
humans and is therefore an essential prerequisite for a successful pregnancy, is also found in
homologous form in the spike proteins of SARS viruses. There is no indication whether
antibodies against spike proteins of SARS viruses would also act like anti-Syncytin-1
antibodies. However, if this were to be the case this would then also prevent the formation of a
placenta which would result in vaccinated women essentially becoming infertile. To my
knowledge, Pfizer/BioNTech has yet to release any samples of written materials provided to
patients, so it is unclear what, if any, information regarding (potential) fertility-specific risks
caused by antibodies is included.
According to section 10.4.2 of the Pfizer/BioNTech trial protocol, a woman of childbearing
potential (WOCBP) is eligible to participate if she is not pregnant or breastfeeding, and is using
an acceptable contraceptive method as described in the trial protocol during the intervention
period (for a minimum of 28 days after the last dose of study intervention).
This means that it could take a relatively long time before a noticeable number of cases of postvaccination infertility could be observed.
XII. It appears that Pfizer/BioNTech have not yet released any samples of written materials
provided to patients, so it is unclear what, if any, instructions/information patients/subjects were
given regarding ADE and PEG-related issues and (potential) fertility- or pregnancy-specific
issues.